Source comparison
Best BPC-157 Dosage for Joint Support: Comparison Across Injury Models
Acute tendon rupture 200–300mcg daily Subcutaneous, 1–2cm from rupture site 14–28 days VEGF upregulation, angiogenesis, collagen type I synthesis Achilles, patellar, rotator cuff tears. Models show 60–70% improvement in tensile strength versus controls Chronic
This comparison does not assign a generated winner or score.
- Acute tendon rupture
- 200–300mcg daily
- Subcutaneous, 1–2cm from rupture site
- 14–28 days
- VEGF upregulation, angiogenesis, collagen type I synthesis
- Achilles, patellar, rotator cuff tears. Models show 60–70% improvement in tensile strength versus controls
- Chronic tendinopathy
- 250–350mcg daily
- Peri-tendon subcutaneous, rotated sites
- 6–8 weeks
- Growth hormone receptor modulation, fibroblast proliferation
- Tennis elbow, jumper's knee. Addresses collagen disorganization rather than acute inflammation
- Ligament sprain/tear
- 300–400mcg daily
- Adjacent to affected ligament
- 4–6 weeks
- Nitric oxide pathway modulation, ECM remodeling
- ACL, MCL injuries. Enhances ligament-to-bone healing interface
- Osteoarthritis / cartilage degeneration
- 400–500mcg daily
- Intra-articular or peri-articular subcutaneous
- 8–12 weeks
- Chondrocyte proliferation, reduction of inflammatory cytokines
- Knee OA models show reduced cartilage degradation markers; requires extended protocol due to avascular cartilage
- Meniscal damage
- Peri-meniscal subcutaneous
- 6–10 weeks
- ECM preservation, reduction of MMP activity
- Partial meniscal tears. Models suggest reduced progression to full-thickness tear